Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

US9718806B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• David Yunzhi Li · Shanghai, CN
• Jiabing Wang · Lansdale, US
• Zhenfan Yang · Shanghai, CN
• Qingbei Zeng · Shanghai, CN
• Xiaolin Zhang · Singapore, SG

Key dates

• Filing date: May 24, 2016
• Grant date: Aug 1, 2017
• Expiry date: May 24, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof:which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.